Pharmacogenetics of sulfonylurea-induced hypoglycemia in Type 2 diabetes patients: the SUCLINGEN study-Reference-Cited by-同舟云学术

Pharmacogenetics of sulfonylurea-induced hypoglycemia in Type 2 diabetes patients: the SUCLINGEN study

Published:2021-11 Issue:16 Volume:22 Page:1057-1068
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Loganadan Navin Kumar¹²^ORCID,Huri Hasniza Zaman²³^ORCID,Vethakkan Shireene Ratna⁴,Hussein Zanariah⁵

Affiliation:

1. Department of Pharmacy, Putrajaya Hospital, Precinct 7, Putrajaya, 62250, Malaysia

2. Faculty of Pharmacy, University of Malaya, Kuala Lumpur, 50603, Malaysia

3. Clinical Investigation Centre, 5th Floor, East Tower, University of Malaya Medical Centre, Lembah Pantai, 59100, Kuala Lumpur, Malaysia

4. Division of Endocrinology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia

5. Department of Medicine, Putrajaya Hospital, Precinct 7, Putrajaya, 62250, Malaysia

Abstract

Aim: This study investigated the incidence of sulfonylurea-induced hypoglycemia and its predictors in Type 2 diabetes (T2D) patients. Patients & methods: In this prospective, observational study, T2D patients on maximal sulfonylurea-metformin therapy >1 year were enrolled. Hypoglycemia was defined as having symptoms or a blood glucose level <3.9 mmol/l. Results: Of the 401 patients, 120 (29.9%) developed sulfonylurea-induced hypoglycemia during the 12-month follow-up. The ABCC8 rs757110, KCNJ11 rs5219, CDKAL1 rs7756992 and KCNQ1 rs2237892 gene polymorphisms were not associated with sulfonylurea-induced hypoglycemia (p > 0.05). Prior history of hypoglycemia admission (odds ratio = 16.44; 95% CI: 1.74–154.33, p = 0.014) independently predicted its risk. Conclusion: Sulfonylurea-treated T2D patients who experienced severe hypoglycemia are at increased risk of future hypoglycemia episodes.

Funder

Universiti Malaya

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2021-0059

Reference45 articles.

1. Do sulphonylureas still have a place in clinical practice?

2. Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus

3. Treatment Patterns Among Older Patients with Type 2 Diabetes in the United States: A Retrospective Cohort Study

4. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications

5. Mortality risk with sulphonylureas compared to metformin

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glyburide confers neuroprotection against age-related macular degeneration (AMD);Translational Research;2024-10

2. Relationship between the efficacy of sulfonylurea therapy and structural variants of the ABCC8 (rs757110) and KCNJ11 (rs5219) genes in patients with type 2 diabetes mellitus with different phenotypes;Сибирский научный медицинский журнал;2024-04-27

3. Multidisciplinary Advances Address the Challenges in Developing Drugs against Transient Receptor Potential Channels to Treat Metabolic Disorders;ChemMedChem;2023-01-19